SEARCH RESULTS FOR: "Tag: NASDAQ-ARWR"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2018(4)
CATEGORIES
Analyst Update(1)
Buzz Stocks(1)
Intraday Option Activity(1)
Options Recommendations(1)
Quantitative Analysis(1)
Stock Market News(1)
Stocks On the Move(1)
Unusual Trading Activity(1)
Options Hedges in Demand on Volatile Arrowhead Pharmaceuticals Stock
https://www.schaeffersresearch.com/content/options/2018/05/15/options-hedges-in-demand-on-volatile-arrowhead-pharmaceuticals-stock
5/15/2018 3:10 PM
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) gapped to a three-year high of $10.10 yesterday, before swinging to a loss. Today, the shares have resumed their longer-term uptrend, adding 2.3% to trade a...
2 Upgraded Drug Stocks Squeezing Shorts
https://www.schaeffersresearch.com/content/news/2018/05/09/2-upgraded-drug-stocks-squeezing-shorts
5/9/2018 10:21 AM
T2 Biosystems Inc (NASDAQ:TTOO) was upgraded to "buy" from "neutral" at Janney, after the sepsis specialist reported first-quarter revenue of $2.3 million -- well above the consensus estimate of $1.4 ...
Analyst Notes Lift ARWR, DVAX Stocks; ESPR Jumps On Drug Data
https://www.schaeffersresearch.com/content/news/2018/03/27/analyst-notes-lift-arwr-dvax-stocks-espr-jumps-on-drug-data
3/27/2018 2:03 PM
The Dow is holding higher this afternoon thanks to a strong move from GE stock. Three other names making notable moves today are drug stocks Esperion Therapeutics Inc (NASDAQ:ESPR), Arrowhead Pharm...
Buy Calls On These 2 Biotech Stocks
https://www.schaeffersresearch.com/content/analysis/2018/03/13/buy-calls-on-these-2-biotech-stocks
3/13/2018 3:03 PM
Pharmaceutical stocks went on a tear recently, with the iShares Nasdaq Biotechnology ETF (IBB) fresh off a seven-day winning streak -- its longest series of consecutive gains since March 2015. While...
Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.
More About
Schaeffer's
Contact
Us
Partner Center